Nuclera

Cambridge, United Kingdom · Founded 2013 · Privately Held (backing)

Developer of a protein prototyping system designed to accelerate drug discovery workflows. Nuclera is based in Cambridge, United Kingdom and was founded in 2013. It was valued at $155 million at its Series B in Jul 2022, the last priced event on record. It has raised $166 million across 9 recorded rounds; the latest was an $87 million Series C in Jan 2026.

PMV mark · valuation
$154.5M
Oct 2026
Priced at
its Series B
Jul 2022
Total raised
$166.1M
Last round
Later Stage VC (Series C)
Jan 2026

Capitalization table

2 share classes, by liquidation seniority
ClassLiq. prefIssue price
Ordinary▮▮
Series B▮▮
Preferences, participation and issue prices are Pro.Unlock preferences + participation

Membership and data by Private Market View

Free account
More of Nuclera with a free account
  • ·Post-money valuations for 2 rounds
  • ·The complete investor list: 22 names
  • ·Watch Nuclera: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Reading Nuclera's cap table

Share classes are listed senior-first: in a sale or liquidation, higher-seniority preferred stock is paid its liquidation preference before junior classes and common see proceeds. A participating class takes its preference and shares in the remainder; a non-participating class chooses one or the other.

The original issue price is what investors paid per share in that class’s round — read against current secondary prices, it shows which investors are above or below water.

Frequently asked about Nuclera

How many share classes does Nuclera have?
Nuclera has 2 recorded share classes, listed by liquidation seniority — Ordinary is the most senior.
How many shares has Nuclera authorized?
Across its 2 recorded classes, Nuclera has authorized 3,949,990 shares.
Where does Nuclera's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Nuclera's 9 recorded funding rounds.